MarketPulse

pharmaceutical development

12 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Hemophilia Treatment Revolution: 50+ Companies Race to Transform Patient Care

Over 50 drugmakers advance 55+ hemophilia treatments as Novo Nordisk and competitors pursue gene therapies and next-gen factors.
NVORHHBYREGNBAYRYMGXclinical trialsgene therapy
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Novo Nordisk Bets on OpenAI Partnership to Reshape Drug Development Economics

Novo Nordisk partners with OpenAI to accelerate drug discovery via AI. Long-term benefits possible, but near-term headwinds from competition and clinical setbacks persist.
LLYNVOclinical trialsdiabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nxera Pharma Hits $10M Milestone with AbbVie on Neurology Drug Discovery

Nxera Pharma receives $10M payment from AbbVie for identifying validated drug molecules against neurological disease target using proprietary platform.
ABBVpharmaceutical developmentcollaboration
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

90+ Companies Racing to Transform Psoriasis Treatment Landscape

Over 90 pharmaceutical companies are advancing 100+ psoriasis drugs through clinical trials, with major players like Takeda and Alumis posting positive Phase III results.
SNGXTAKFBLGCANFALMS+1clinical trialsbiologics
BenzingaBenzinga··Vandana Singh

Novo Nordisk Partners With OpenAI to Revolutionize Drug Discovery Pipeline

Novo Nordisk partners with OpenAI to deploy AI across drug discovery, clinical trials, manufacturing, and supply chain operations, targeting pilot programs by end of 2026.
NVOartificial intelligenceoperational efficiency
GlobeNewswire Inc.GlobeNewswire Inc.··Na

XORTX Bolsters Kidney Disease Pipeline With $3M Vectus Acquisition

XORTX acquires Vectus kidney fibrosis asset VB4-P5 for $3M, expanding pipeline in high-potential CKD therapeutics market.
XRTXacquisitionkidney disease
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Pharma Giants Race to Dominate Severe Asthma Market With 35+ Pipeline Drugs

Over 30 pharma companies develop 35+ severe asthma drugs with recent approvals validating new mechanisms, signaling major market opportunity and competitive intensity ahead.
AZNUPBGSKGENBFDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Curanex Advances Phyto-N Toward Late-Stage Development as Clinical Timeline Solidifies

Curanex advances Phyto-N toward IND submission in Q4 2026, completing manufacturing and toxicology milestones with secured 12-month funding.
CURXclinical trialspharmaceutical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

XORTX Shareholders Greenlight Board Overhaul and Share Consolidation

XORTX Therapeutics shareholders approved all proposals at March 24 meeting with 35% representation, including new leadership and share consolidation.
XRTXclinical trialskidney disease
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Kdventures Ab

Organon Discontinues Second Forendos Drug Candidate, KDventures Faces Total Loss

Organon discontinues second Forendo drug candidate for PCOS, eliminating all programs from 2021 acquisition. KDventures writes off remaining contingent consideration entirely.
OGNpharmaceutical developmentdrug development discontinuation
BenzingaBenzinga··Vandana Singh

Teva Advances Monthly Schizophrenia Injection Toward FDA Approval

Teva's once-monthly schizophrenia injection TEV-749 advances toward FDA approval, aiming to improve patient medication compliance and reduce healthcare burden compared to daily oral treatments.
TEVAFDA approvalschizophrenia treatment